Loading…
IceCure Medical Ltd.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in ICCM.
▼ -99.2% over 5Y.
today you would have $6.55▼ -99.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $18.30 | $33.00 | $32.10 | $46.50 | $91.50 | |
| P/E | 3.4x | 2.5x | 3.7x | 3.3x | 3.4x | 8.7x |
| P/S | 18.9x | 13.2x | 18.9x | 15.2x | 22.9x | 26.4x |
| P/B | 4.0x | 4.9x | 9.0x | 4.0x | 2.8x | 4.0x |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| TRIBTrinity Biotech PLC | $9.68 | — | — | — | — | $7.87M |
| AIMAIM ImmunoTech Inc. | $0.26 | — | 1.0x | — | -2382.30% | $7.87M |
| SKYESkye Bioscience, Inc. | $1.78 | — | — | — | -233.87% | $7.86M |
| ITOCiTonic Holdings Ltd | $0.32 |
IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MSense, a multi probe system for the treatment of multiple and larger tumors. The company serves hospitals, interventional radiological centers, ambulatory centers, and private clinics. IceCure Medical Ltd was incorporated in 2006 and is headquartered in Caesarea, Israel.
Company description provided by Yahoo Finance.
| EPS | $7.20 | $9.00 | $9.60 | $13.80 | $10.50 |
| Profit margin | -453.76% | -445.61% | -465.45% | -453.76% | -550.34% | -239.13% |
| ROE | -120.46% | -166.36% | -221.97% | -120.46% | -66.78% | -36.71% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.9x |
| — |
| -71.25% |
| $7.83M |
| AIDX20/20 Biolabs, Inc. | $0.62 | — | 4.7x | — | -331.22% | $7.97M |
| ENSCEnsysce Biosciences, Inc. | $0.40 | — | — | — | -1295.09% | $7.78M |